stockrowPrelude Therapeutics Incorporated
PRLD Healthcare Biotechnology
Prelude Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.1 million, up 73.4% from fiscal 2024.
- Revenue
- +42.6%
- EPS
- +65.9%
- Free cash flow
- +40.3%
Quarter to June 2026, against a year earlier
Follow PRLD
Alert me
Prelude Therapeutics Incorporated (PRLD) Beneish M-score
Prelude Therapeutics Incorporated's Beneish M-score for fiscal 2025 cannot be worked out: days’ sales in receivables index cannot be worked out.
Beneish M-score, annual
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | — | — | n/a | — |
| Gross margin index | 1.00 | — | 0.53 | |
| Asset quality index | 1.15 | — | 0.47 | |
| Sales growth index | 1.73 | — | 1.55 | |
| Depreciation index | (3.54) | — | −0.41 | |
| SG&A index | 0.45 | — | −0.08 | |
| Total accruals to total assets | (0.31) | — | −1.43 | |
| Leverage index | 2.57 | — | −0.84 | |
| Beneish M-score | n/a — days’ sales in receivables index cannot be worked out | — | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| ENTA Enanta Pharmaceuticals, Inc. compare | −4.3× |
| AGEN Agenus Inc. compare | 12.6× |
| FULC Fulcrum Therapeutics, Inc. compare | 21.2× |
| KYTX Kyverna Therapeutics, Inc. compare | — |
| SCTX Scribe Therapeutics Inc. compare | — |
| PRLD Prelude Therapeutics Incorporated | — |
| NAUT Nautilus Biotechnology, Inc. compare | — |
| DTIL Precision BioSciences, Inc. compare | — |
| OCGN Ocugen, Inc. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI